Söylemez Cem Murat, Gürsoy Pinar, Şanli Ulus Ali
Department of Medical Oncology, University of Health Science Izmir Tepecik Research and Training Hospital, Bornova, Izmir 35110, Turkey.
Department of Medical Oncology, Ege University Faculty of Medicine, Bornova, Izmir 35100, Turkey.
Oncol Lett. 2024 Dec 17;29(3):102. doi: 10.3892/ol.2024.14848. eCollection 2025 Mar.
The present study was a retrospective single-center study. A total of 81 patients diagnosed with metastatic soft tissue sarcoma were included who received pazopanib therapy. Clinical data, including age at diagnosis, histological subtype, treatments received before pazopanib, number of metastatic sites at the time of initiation of treatment, progression-free survival and overall survival time under pazopanib treatment, side effects and response evaluation in follow-up imaging after initiation of pazopanib therapy, were recorded. The 81 patients had 11 different histological subtypes. The synovial sarcoma, leiomyosarcoma and pleomorphic sarcoma groups included 51 patients in total. The median overall survival time in the entire study cohort was 46 months, and the median progression-free survival time was 5 months. The clinical response rate was 46.3%. Patients with hemangioendothelioma and alveolar soft part sarcoma exhibited an improved response to treatment compared with that of patients with other subtypes. Line of therapy and tumor grade were not significantly associated with progression-free survival or clinical response. It was concluded that, regardless of subtype, patients with a low tumor grade and a small number of metastatic sites exhibited an improved response; although the difference in response for patients with a low tumor grade was not significant. In addition, administering the treatment as a second- or third-line therapy appeared to be more appropriate compared with administering it as a later-line therapy; however, this difference was not found to be statistically significant. Therefore, pazopanib should be evaluated as an option for a selected group of patients in whom these factors present together. A further advantage of pazopanib demonstrated was that treatment tolerance was generally good.
本研究为一项回顾性单中心研究。共纳入81例接受帕唑帕尼治疗的转移性软组织肉瘤患者。记录临床数据，包括诊断时的年龄、组织学亚型、帕唑帕尼治疗前接受的治疗、开始治疗时的转移部位数量、帕唑帕尼治疗期间的无进展生存期和总生存期、副作用以及帕唑帕尼治疗开始后随访影像学中的反应评估。这81例患者有11种不同的组织学亚型。滑膜肉瘤、平滑肌肉瘤和多形性肉瘤组共有51例患者。整个研究队列的中位总生存期为46个月，中位无进展生存期为5个月。临床缓解率为46.3%。与其他亚型患者相比，血管内皮瘤和腺泡状软组织肉瘤患者对治疗的反应有所改善。治疗线数和肿瘤分级与无进展生存期或临床反应无显著相关性。研究得出结论，无论亚型如何，肿瘤分级低且转移部位数量少的患者反应有所改善；尽管肿瘤分级低的患者在反应上的差异不显著。此外，与作为更晚期治疗线数给药相比，作为二线或三线治疗给药似乎更合适；然而，未发现这种差异具有统计学意义。因此，对于这些因素同时存在的特定患者群体，应评估帕唑帕尼作为一种选择。帕唑帕尼显示的另一个优点是治疗耐受性总体良好。
